LDN193189 also suppressed clonogenicity and decreased the CSC-enriched ALDH1+ population in malignant breast tumors, and in a mouse model of breast cancer treated with LDN193189, a reduction in the expression of EMT-associated markers was observed [96]. This evidence concerns the gene ALDH1A1 and breast cancer.